Candel's CEO looks to help ignite a new era of cancer treatments

Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.

By Taren Grom • Feb. 28, 2022

Why plasma derived therapies have a unique edge in rare diseases

Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.

By Kim Ribbink • Feb. 25, 2022

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

Guadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues

A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company. 

By Robin Robinson • Feb. 25, 2022

Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo

Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.

By Taren Grom • Feb. 23, 2022

Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market

The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.

By Kelly Bilodeau • Feb. 23, 2022

How Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'

Why sexual health and telemedicine are key to the company's goals in oncology.

By Meagan Parrish • Feb. 16, 2022

Winning buy-in from early stage biotech investors

The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.

By Taren Grom • Feb. 11, 2022

Industry executives on the milestone moments shaping pharma's future

Scientific, technological, and communication changes that are making a permanent impact on the industry.

By Taren Grom • Feb. 9, 2022

Innovation vs. invention

IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

By Taren Grom • Feb. 9, 2022

Gaining real-world results from a decentralized trial

Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.

By Kelly Bilodeau • Feb. 8, 2022

Home is where the trial is

Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials. 

By Kelly Bilodeau • Feb. 7, 2022

Pharma's pain points with AI

Looking beyond the buzz and at the challenges associated with AI.

By Meagan Parrish • Feb. 7, 2022

Industry executives predict the next 'blue oceans' in pharma

Where life science leaders see breakthroughs happening in the industry.

By Taren Grom • Feb. 4, 2022

Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics

With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.

By Robin Robinson • Feb. 3, 2022

PTC's vice president of patient relations outlines the importance of patient input in rare disease R&D

You can't know what matters to rare disease patients unless you ask them.

By Kim Ribbink • Feb. 3, 2022

New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality

Read what Capsida CEO Peter Anastasiou has planned for his new role. 

By Taren Grom • Feb. 3, 2022

Talent acquisition stays top of mind for pharma execs

From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.

By Taren Grom • Feb. 1, 2022

For the CEO of Travere, running a rare disease company is personal

To kick off Rare Disease month, we interview the CEO of Travere Therapeutics

By Kim Ribbink • Feb. 1, 2022

Foghorn's CEO on why collaborations are key to unlocking precision medicine

With a major development deal under his belt, Adrian Gottschalk is helping the company advance its innovative platform.

By Robin Robinson • Jan. 28, 2022

Taking the leap and not having all the answers: How incoming CEO Kate Haviland plans to lead Blueprint

For Haviland, success in biotech is about more than drug development.

By Alexandra Pecci • Jan. 28, 2022

Biopharma's R&D leaders on how technology can accelerate drug development

How emerging digital tools are providing enhanced clinical insights and improved trial results.

By Taren Grom • Jan. 27, 2022

How AI is helping pharma solve some of its COVID problems

With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.

By Meagan Parrish • Jan. 25, 2022

One man's quest to boost the patient's role in clinical trials

How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.

By Robin Robinson • Jan. 24, 2022

Leaders predict improving patient engagement will lead to growth opportunities

Why patient engagement is key to successful business growth.

By Taren Grom • Jan. 24, 2022

Evofem CEO Saundra Pelletier aims to level the playing field between men's and women's health

Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.

By Alexandra Pecci • Jan. 23, 2022